A closer inspection of diabetes-related stigma: why more research is needed
- PMID: 32206476
- PMCID: PMC7082436
- DOI: 10.1007/s13340-019-00421-w
A closer inspection of diabetes-related stigma: why more research is needed
Abstract
In the past few years, diabetes-related stigma has rapidly gained attention around the world. Many studies, including our study, show that a diabetes population is globally impacted by disease-specific stigma across age, gender, educational levels, employment status, and race/ethnicity. However, it still remains unclear whether some of these socioeconomic factors are more influential in terms of the social vulnerability of the exposed individuals with type 2 diabetes. Understanding how diabetes-related stigma influences patients through these socioeconomic and racial/ethnic factors, and how these impacts vary according to different patient populations would help us gain a further understanding of diabetes-related stigma as a whole. Thus, most importantly, we should establish a comprehensive, coherent study design (e.g., cross-regional study, cross-national study), identify more vulnerable patient populations, and tackle diabetes-related stigma in collaborative efforts with patients, clinicians, researchers, academic societies, governments, and all involved parties around the globe.
© The Japan Diabetes Society 2019.
Conflict of interest statement
Conflict of interestAsuka Kato has nothing to disclose. Toshimasa Yamauchi reports honoraria from Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Sanofi S.A., Takeda Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis International AG, and Novo Nordisk Pharma Ltd., research funding from AstraZeneca K.K., Kowa Pharmaceutical Co., Ltd., Merck Sharp & Dohme Co., Daiichi Sankyo Co., Ltd., Sanofi S.A., Boehringer Ingelheim GmbH Japan, and AeroSwitch, subsidies or donations from Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., Taisho Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., and Daiichi Sankyo Co., Ltd., and endowed departments by commercial entities from Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corporation, Merck Sharp & Dohme Co., Boehringer Ingelheim GmbH Japan, Kowa Pharmaceutical Co., Ltd., and Asahi Mutual Life Insurance Company. Takashi Kadowaki reports honoraria from Astellas Pharma Inc., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., MSD Corporation, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Terumo Co., Ltd., manuscript fees from Takeda Pharmaceutical Co., Ltd., research funding from AstraZeneca K.K., Daiichi Sankyo Co., Ltd., and Takeda Pharmaceutical Co., Ltd., subsidies or donations from Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., and endowed departments by commercial entities from Asahi Mutual Life Insurance Company, Nippon Boehringer Ingelheim Co., Ltd., Kowa Pharmaceutical Co., Ltd., MSD Corporation, Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd.
References
-
- Virginia V. the most important thing we give to people is hope—overcoming stigma in diabetes and obesity. The 79th American Diabetes Association scientific sessions: American Diabetes Association; 2019. Accessed 22 Nov 2019. https://professional.diabetes.org/webcast/outstanding-educator-diabetes-.... - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous